Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at or call 800-767-3771 ext.  9339.

Genetic products company, Affymetrix Inc. (AFFX - Analyst Report) provided a disappointing guidance for its 2013 first-quarter results, based on available preliminary financial data. The company will report its financial results on Apr 30, after market closes.

Affymetrix expects revenues to be $78 million in the quarter, which is significantly lower than the Zacks Consensus Estimate of $83 million. It is expected to decline about 8% sequentially. Revenues from the acquired eBioscience business contributed $19 million to total revenues. Excluding the impact of eBioscience, revenues are likely to decline 9.5% year over year.

Management pointed to lower-than-expected gene expression product sales across all regions, particularly Japan, which led to the decline in sales. This offset healthy revenues from genotyping and cytogenetics products and moderate contribution from eBioscience.

Further, Affymetrix had roughly $38 million cash-on-hand as of Mar 31, 2013, after redeeming the remaining $3.9 million of its 3.5% convertible notes and prepaying $3.2 million of senior-secured debt. With current senior secured debt of $70 million, debt repayment is a primary objective of Affymetrix’s management. Affymetrix’s debt-to-equity ratio is 59.7% compared with 7.1% for its peer group.

Based on the disappointing preliminary results, the company currently carries a Zacks Rank #5 (Strong Sell). Research and development spending by Affymetrix’s customers have fallen considerably due to a weak macroeconomic environment coupled with stringent government actions including budget cuts.

On the earnings front, the company’s earnings have failed to beat the Zacks Consensus Estimates once in the last 4 quarters with an average negative surprise of 9.13%. However, it managed to meet estimates in the fourth quarter of 2012 and beat it in the first and third quarters. The current Zacks Consensus Estimate for earnings per share for the first quarter of fiscal 2013 is 1 cent.

While we strongly recommend avoiding the stock, companies like Osiris Therapeutics (OSIR - Analyst Report), Cleveland BioLabs (CBLI - Snapshot Report) and Athersys (ATHX - Snapshot Report), all carrying a Zacks Rank #1 (Strong Buy), are expected to do well in the Medical-Biomed/Gene industry.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%